Photo: Smith Collection/Gado/Getty Images
Memorial Sloan Kettering Cancer Center is partnering with oncology generative AI company Triomics for clinical research.
Memorial Sloan Kettering (MSK) Cancer Center's iHub and Clinical Research Innovation Consortium (CRIC) program is deploying Triomics' AI-powered clinical-trial matching and screening system in active clinical trials.
The collaboration will help the cancer center identify clinical trial opportunities faster by automating the current manual pre-screening process.
WHY THIS MATTERS
Oncology medical records have grown increasingly complex and lengthy, according to Triomics.
At medical centers with large clinical trial portfolios, manual pre-screening against a broad set of clinical trials can take 30-45 minutes per patient, particularly when combing through clinician notes.
AI automatically goes through patient records and surfaces eligible trials with an itemized, criterion-by-criterion rationale and source citations, Triomics said.
As part of the collaboration, MSK will deploy the platform to automatically screen the upcoming appointments against active clinical trials.
THE LARGER TREND
The collaboration involves two phases that will eventually expand the platform’s use in decentralized clinical trials with MSK's satellite clinics and partner institutions in the tri-state area of New York, New Jersey and Connecticut.
Triomics also indicated that the AI platform will be used at other leading cancer centers.
Memorial Sloan Kettering in New York, which has at least nine locations, has institutional financial interests in the AI company, Triomics said. MSK previously worked with Triomics as a participant in the 2024 Cohort of MSK's selective iHub Challenge program.
Paul Sabbatini, senior vice president for Clinical Research at MSK, will join Triomics' Customer Advisory Board on the scale-up of the technology across Triomics' network of partner cancer centers.
ON THE RECORD
"We look forward to working with Triomics on the rollout of this innovative technology. Real-time, evidence-linked matching transforms clinical trial screening from a bottleneck into an enabler. We expect this collaboration to enable our teams to surface opportunities that might otherwise be missed and offer trials to more patients," said Joseph Lengfellner, who is senior director of Clinical Research Information Technology at MSK and manages the CRIC program.
Email the writer: SMorse@himss.org